Mirati Therapeutics Profit Margin

Mirati Therapeutics (MRTX) currently reports a profit margin of -18.76% as of September 2023. That compares with -62.54% in the prior-year period — up 70.0% year over year. That is below the Healthcare sector average of 15.58%. Use the charts on this page to explore Mirati Therapeutics's profit margin history and peer comparisons.

Mirati Therapeutics's profit margin increased from -62.54% to -18.76% — a 70.0% year-over-year increase (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Mirati Therapeutics's profit margin of -18.76% is lower than the Healthcare sector average of 15.58%. That is roughly 12141.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Mirati Therapeutics's current -18.76% should be judged against Healthcare norms (sector average: 15.58%) and against MRTX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -18.76%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.58%. From there, open related valuation or income-statement pages for Mirati Therapeutics, and consider following MRTX for alerts when major investors trade the stock.